Abstract. The immunological mechanism mediated by T cells is the main therapeutic target in the treatment of renal cell carcinoma (RCC) with interleukin (IL)-2 and interferon (IFN)-α. The aim of the present study was to evaluate the role of B7-H4 in the IL-2, IFN-α and IFN-γ treatment of clear cell RCC (ccRCC). A total of 154 paraffin-embedded ccRCC tissues were studied using immunohistochemistry, which subsequently indicated that positive B7-H4 expression is associated with adverse clinical features in ccRCC. The effects of IL-2, IFN-α and IFN-γ on B7-H4 expression in a ccRCC cell line were evaluated at the mRNA and protein levels. In addition, the effect of B7-H4 on the killing activity of T cells was detected. B7-H4 expression was identified to be upregulated by IL-2, IFN-α and IFN-γ, of which, IFN-γ was the most capable. Additionally, blocking of B7-H4/B7-H4 ligand interactions may rescue the killing activity of T cells. Altogether, the observations of the current study showed that the immune escape pathway induced by B7-H4 may be one of the most important reasons for the low efficacy of IL-2 and IFN-α and the inability to observe the efficacy of IFN-γ in mRCC. This indicates that B7-H4 may be used as a new molecular biology marker to select treatment options for patients with ccRCC.
Introduction
Renal cell carcinoma (RCC) is one of the most common types of malignant tumor of the human urinary system. To date, the benefit of conventional therapies for RCC, including surgical, radiological and chemotherapeutic approaches, is limited. Treatment with interferon (IFN) and interleukin (IL)-2 remains the main immunotherapy method for RCC, with the exception of surgery, but only ~10% of advanced RCC patients respond to cytokine-based immunotherapy (1, 2) . Therefore, more effective potential and combined therapies must be found. New targeted therapy for RCC may initiate a new avenue for cancer treatment, and targeted therapy depends on the evaluation of target gene status.
B7-H4, also called B7x/B7s/VTCN1, is the newest B7 superfamily member identified as an inhibitory modulator of the T-cell response. Combined with its receptor, B7-H4 may inhibit the proliferation and cytokine production of CD4 + and CD8 + T cells. The blocking of B7-H4/B7-H4 ligand interactions may restore antitumor T-cell responses to ovarian cancer cells (3) . Previous studies have reported that the B7-H4 + status is an independent predictor of poor prognosis in multivariate analysis (4) (5) (6) (7) (8) (9) . To date, few previous studies have analyzed the potential contributions of B7-H4 to tumoral immune escape and therapeutic targeting in RCC.
Herein, we present evidence for the potential contributions of B7-H4 to tumoral immune escape in ccRCC, which indicates that B7-H4 may be used as a new biological molecular marker for select treatment options in patients with ccRCC.
Materials and methods
Cell culture, antibodies and cytokines. The cell line, 786-0, was purchased from the Cell Bank at the Chinese Academy of Sciences (Beijing, China) and was cultured according to the manufacturer's instructions. The anti-B7-H4 antibody (Ab) was purchased from R&D Systems (Minneapolis, MN, USA). Other Abs were purchased from Bioss (Beijing, China) and the cytokines (IL-2, IFN-α and IFN-γ) were purchased from Xiamen Amoytop Biotech Co., Ltd. (Xiamen, China).
RCC tissue.
A total of 154 specimens of RCC tissue were collected from RCC patients undergoing radical nephrectomy in the Department of Urology, Zhejiang Cancer Hospital (Hangzhou, China). The final staging, grading and histological diagnosis were based on the pathology report. ELISA to cell culture supernatant. The protein of B7-H4 was diluted to 100, 50, 25, 10, 2, 0.5 and 0.1 ng/ml to be used as a standard. Samples were collected following centrifugation at 1,200 x g. In total, 40 µl sample, 10 µl anti-B7-H4 Ab and 50 µl streptomycin-horseradish peroxidase were added into the ELISA kit and then incubated for 1 h at 37˚C. Following washing three times with phosphate-buffered saline (PBS), 100 µl chromogenic agent was added to each well. In addition, 50 µl stop buffer was added to each well following incubation for 15 min at 37˚C. The plates were then read at 450 nm using a spectrophotometer. The minimum detectable concentration was determined to be >0.1 ng/ml.
B7-H4 expression and its role in interleukin-

Reverse transcription (RT)-polymerase chain reaction (PCR).
Total RNA was extracted from the 786-0 cells using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) following stimulation with IL-2, IFN-α and IFN-γ (1,000 U/ml) for 24 h. A total of 2 µg RNA was reverse-transcribed using avian myeloblastosis virus reverse transcription XL (Toyobo Co. Ltd, Shanghai, China) for 90 min at 42˚C in the presence of oligo(dT) primer (Fermentas, Waltham, MA, USA). PCR was performed using Taq polymerase. The primer sequences (Ying Wei Chuang, Guangzhou, China) used were as follows: B7-H4 forward, 5'-CACTCATCATTGGCTTTGGTATTTCAG-3' and reverse, 5'-CGACAGCTCATCTTTGCCTTCTTTG-3'; and actin forward, 5'-AGCGGGAAATCGTGCGTGAC-3' and reverse, 5'-ACTCCTGCTTGCTGATCCATATC-3'. PCR was performed for 35 cycles, which consisted of a pre-soak for 5 min at 94˚C, denaturing for 30 sec at 94˚C, annealing for 30 sec at 56˚C and extension for 30 sec at 72˚C. Following completion of the cycle, the amplified products were electrophoresed through a 1% agarose gel and stained with ethidium bromide. Images were captured under an ultraviolet light transilluminator (Syngene Co., Cambrisge, UK). 
Results
Increased B7-H4 expression is associated with adverse clinical features. In total, 91 (59.09%) patient specimens exhibited positive tumor B7-H4 staining (Fig. 1A) . A comparison of clinical features by tumor B7-H4 expression is shown in Table I . Positive tumor B7-H4 expression was associated with adverse clinical features, including tumor-node-metastasis and clinical stages.
IL-2, IFN-α and IFN-γ may upregulate B7-H4 expression in 786-0 cells.
The CCK-8 assay, a proliferation assay that is directly proportional to the number of live cells in culture, was used as an independent measure of the proliferation in the IL-2-, IFN-α-and IFN-γ-treated 786-0 cells. These results supported the fact that IL-2, IFN-α and IFN-γ may inhibit the proliferative activity of 786-0 cells and exhibit a significant dose-effect correlation. The maximum drug concentration of a 1% cellular proliferation inhibition rate was 1,000 U/ml. IL-2, IFN-α and IFN-γ were applied at this concentration to stimulate the 786-0 cells in order to study the effect of IL-2, IFN-α and IFN-γ on B7-H4 expression in ccRCC cells. The RT-PCR and IHC results showed that the protein (Fig. 2) and mRNA ( Fig. 3) expression of B7-H4 may be upregulated by IL-2, IFN-α and IFN-γ, of which, IFN-γ was the most capable. TNM, tumor-node-metastasis. 
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44.89±0.97 ng/ml, 46.74±2.25 ng/ml and 47.31±1.12 ng/ml, respectively, in which the differences were statistically significant (P<0.05). Flow cytometry (Fig. 4) 
B7-H4 is a negative regulator of T-cell cytotoxicity.
To determine the role of B7-H4 in T-cell responses, different ratios of effector to target cells (30:1, 20:1 and 10:1) were applied. CCK-8 was used to detect the cytotoxicity of the T cells. The results showed that masking B7-H4 with a specific blocking Ab increased the T-cell killing of the 786-0 cells (P<0.05). With the increase of the concentration of effector cells, the cytotoxicity also increased significantly (P<0.05). This identified the inhibitory role of B7-H4 in T cell-dependent cytotoxicity, as in other tumor cell models (3).
Discussion
RCC is a typical immunogenic tumor frequently harboring high levels of tumor-infiltrating T lymphocytes and occasionally exhibiting spontaneous regression of metastases following primary tumor removal (10-12). As it is refractory to radiation and chemotherapy, immunotherapy, including the use of IFN-α and IL-2, is the main treatment choice for mRCC without surgery. However, in previous studies, the efficacy of IL-2 and IFN-α has been extremely low in mRCC and it has not been possible to observe the efficacy of IFN-γ (1,2). The costimulatory B7 family members not only provide positive signals to stimulate T-cell activation, but also deliver negative signals to inhibit T-cell responses. Identified in 2003, B7-H4 represents the newest member of the B7 family of costimulatory ligands (13) (14) (15) . Despite widespread B7-H4 mRNA expression in various human tissues, the lack of immunohistochemical staining of B7-H4 in the majority of normal human tissues indicates that the expression of B7-H4 is relatively restricted (6) . B7-H4 is a type Ⅰ transmembrane protein, and expression may be detected in various types of human cancer tissues, including breast (4), ovarian (5), pancreatic (6) and lung (7) cancer, melanoma (8) and RCC (9) . The expression of B7-H4 has been found to correlate with advanced stages, poor patient survival and tumor infiltration by T regulatory cells (16) , which made it a candidate of choice for targeted therapy. Notably, in the present study, positive B7-H4 expression was associated with adverse clinical features in ccRCC, which indicated that B7-H4 may be a feasible candidate of choice for RCC-targeted therapy.
Tumor infiltrating lymphocytes may be a manifestation of antitumor immunity, but a more abundant infiltration of tumor tissue T cells has been associated with a shorter survival of the RCC patients (11), which indicated that there is a potential failure mechanism of T-cell immunity in RCC tissues. The immunological mechanism mediated by T cells is also the main therapeutic target in the IL-2 and IFN-α treatment of mRCC patients. The results of the present study demonstrated that IL-2, IFN-α and IFN-γ may upregulate the expression of B7-H4, which may inhibit the proliferation and cytokine production of CD4 + and CD8 + T cells. Additionally, IFN-γ was found to be the most capable for this, which indicated that the immune escape pathway induced by B7-H4 may be one of the most important reasons for the low efficacy of IL-2 and IFN-α and the inability to observe the efficacy of IFN-γ in mRCC treatment. The current study further evaluated the functional ability to reverse T-cell inhibition mediated by the B7-H4 protein, which indicated that masking B7-H4 with a specific blocking Ab may increase the cytotoxicity of T cells in ccRCC. These results confirmed that B7-H4 is a regulatory molecule engaged in negative signaling that impacts anti-responses mediated by T cells in ccRCC, and also establishes a new paradigm for ccRCC cell eradication using B7-H4-based targeting. The study indicates that the blocking of B7-H4/B7-H4 ligand interactions may represent a feasible therapeutic strategy for ccRCC.
Targeting immune checkpoint molecules, such as CTLA4 and B7-H1, has elicited marked clinical responses, particularly in patients with pre-existing immune responses (17) (18) (19) . Based on our studies, we propose that the blocking of B7-H4/B7-H4 ligand interactions may be used as a potential treatment for RCC patients. In addition, B7-H4 detection may be used to select the appropriate treatment for RCC patients. RCC patients whose TMA shows positive expression of B7-H4 must not select IFN-α/IL-2 treatment alone, since the T-cell-mediated antitumor responses must have been repressed by the B7-H4 mediated immune escape pathway. B7-H4 blocking treatment alone or combined with IFN-α/IL-2 may be more suitable for B7-H4 + patients.
